Evaluating blood markers in children with lupus
Official title: Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients : Correlation With Disease Activity and Chronic Organ Damage in These Patients
Run by Sohag University · NCT06718283 · Data updated 2026-11-12
This study looks at blood markers in children with lupus to see how they relate to the severity of the disease and any long-term damage it may cause.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 18 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | November 30, 2024 |
| Main results expected | October 15, 2025 |
| Study ends | February 2, 2026 |
| Registry record updated | December 5, 2024 |
| Trial ID | NCT06718283 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children diagnosed with juvenile systemic lupus erythematosus who meet specific diagnostic criteria.
✕Probably not a fit
Patients with adult-onset lupus or other chronic inflammatory disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the relationship between various hematologic indices in children diagnosed with juvenile systemic lupus erythematosus (SLE) and their correlation with disease activity and chronic organ damage. Researchers will calculate important indices such as the systemic inflammatory index and correlate these with established disease activity and damage indices. The observational nature of the study allows for a comprehensive analysis of these relationships without any interventions.
Why it matters
Potential benefit: If successful, this study could provide valuable biomarkers for monitoring disease activity and organ damage in juvenile lupus patients.
How similar studies have gone: While there have been studies on hematologic indices in lupus, this specific correlation in juvenile patients is less explored, making this approach somewhat novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who fillful 2012 SLICC criteria or 2019 ACR/EULAR criteria of systemic lupus erythematosus * Age of patients at disease onset before 18 years Exclusion Criteria: * Adult onset disease ( age at disease onset after 18 years * Any other chronic inflamatory disorders or other autoimmune diseases
Where it's running
-
Faculty of medicine
Sohag, Egypt Recruiting
Study contacts
- Study coordinator: Alshimaa H Khalaf
- Email: elshimaa011054@med.sohag.edu.eg
- Phone: 01067790054
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases
This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.
-
Trauma registry at Sohag University Hospital
This study tests the creation of a trauma registry in the emergency department to collect data on injured adults admitted with polytrauma at Sohag University Hospital.
-
Prevalence of Myocardial Bridging and its relation to Coronary Plaques on MDCT
This study tests how common myocardial bridging is and whether it relates to coronary plaque in patients undergoing coronary CT angiography.
-
Septoplasty: see if it changes headache symptoms
This study tests whether septoplasty can change headache severity in adults with septal deviation and headache.
-
Predicting SLE Flares with Patient Reports and Machine Learning
Aims to test a low-cost, patient-reported outcome–based machine learning tool to see if it can detect lupus flares early and support care, especially in settings with limited resources.
-
Is geographic mismatch linked to short-term major heart problems after long drug-eluting stent placement?
This study checks whether geographic mismatch can predict short-term major adverse cardiovascular events after a long drug-eluting stent is placed in the coronary arteries.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.